Eli Lilly Raises Sales Outlook as Zepbound Demand Surges

The story so far

7 publishers have covered this in 11 articles since 28 Oct 2026. STAT published first, on 28 October at 10:45 UTC; All Content from Business Insider followed 0 min later. The most recent article, from Bloomberg Markets, appeared on 29 October at 14:12 UTC.

Outlets reporting it: News Feed (major outlet), CNBC (major outlet), Bloomberg Markets (major outlet), STAT, All Content from Business Insider, Quartz, MarketWatch.

3 prediction markets price this story:

• Eli Lilly — the market puts it at 9%, closing 1 Jan 2027. The outcome is Yes if the U.S. federal government takes any financial stake in Eli Lilly before January 1, 2027. Otherwise, the outcome is No. Readers often mistake the linked news story about Novo Nordisk for a relevant event, but only actions by the U.S. federal government regarding Eli Lilly count.
• Omvoh — resolved “No” on 29 Oct 2026. The outcome is Yes if an Eli Lilly representative mentions Omvoh during the next live earnings call or official broadcast, including the question-and-answer session. The outcome is No if they do not mention it in that specific setting. Readers often mistake any general press release or social media post for a valid source, but only the live call or official broadcast counts.
• Above 110 — the market puts it at 99%, with $4k traded in the last 24 hours, closing 7 Nov 2026. The market resolves to Yes if the Carbon Arc Eli Lilly Credit Card Spend for October 2026 exceeds 110. It resolves to No if that spend is 110 or lower. Readers often mistake the linked news headline about sales outlooks as the deciding factor, but only the specific credit card spend data matters.

Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.